News Releases Keyword search Year None202220212020201920182017201620152014201320122011201020092008 5/20/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference 5/19/2022 AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® 5/16/2022 AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update 5/10/2022 AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia 5/9/2022 AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 4/27/2022 AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program 4/25/2022 Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 4/21/2022 AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 3/31/2022 AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures 3/29/2022 AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit Current page 1 Page 2 Next page next › Last page last » Print Page RSS Feeds
Keyword search Year None202220212020201920182017201620152014201320122011201020092008 5/20/2022 AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference 5/19/2022 AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® 5/16/2022 AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update 5/10/2022 AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia 5/9/2022 AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 4/27/2022 AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program 4/25/2022 Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 4/21/2022 AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 3/31/2022 AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures 3/29/2022 AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit Current page 1 Page 2 Next page next › Last page last »
5/16/2022 AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022 AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia
4/25/2022 Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022
4/21/2022 AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022
3/31/2022 AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures
3/29/2022 AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit
